A secondary analysis of the SODa-BIC randomized clinical trial using multiple hierarchical composite outcomes.

Crit Care SciSep 28, 2026 (epub)
Clinical ResearchNephrologyInternal Medicine (General)

Humphrey G M Walker, Alastair Brown, Kyle C White et al.

✦ AI-curated · Sources linked

In 30 seconds

This post-hoc analysis of the SODa-BIC randomized trial evaluated the effects of sodium bicarbonate on Major Adverse Kidney Events at 30 days in critically ill patients with metabolic acidosis. The analysis found no overall treatment effect, with a win ratio of 0.97 (95%CI 0.79 - 1.19), although individual components showed varying effects.

Key findings

  • The win ratio for sodium bicarbonate treatment was 0.97 (95%CI 0.79 - 1.19).
  • Desirability of Outcome Ranking probability was 0.49 (95%CI 0.45 - 0.54).
  • Significant treatment effect modification was observed in subgroups defined by acute kidney injury and severity of acidemia.

Why it matters

Understanding the effects of sodium bicarbonate in critically ill patients with metabolic acidosis is crucial for optimizing treatment strategies and improving patient outcomes, particularly regarding kidney health.

Source

PubMed · PMID 42820515

Published in Crit Care Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.